Abstract:e17565 Background: BRCA1 and BRCA2 are tumour suppressor genes, involved in the homologous repair of double-stranded DNA breaks, located at 17q21.31 and 13q13.1, respectively. Germline BRCA1/2 mutations are identified in 13-15% of ovarian cancers (OC), while an additional 5-7% of ovarian cancers harbor somatic BRCA1/2 mutations among foreign populations. To determine the landscape of germline and somatic pathogenic BRCA1 and BRCA2 alterations in Chinese patients with ovarian cancer tested by next‐generation sequencing (NGS), with the aim of defining the best strategy to be implemented in future routine testing. Methods: 472 normal-paired samples from Chinese patients with ovarian cancers were analyzed using hybridization capture-based next generation sequencing. Somatic and germline mutations were identified including 500 genes associated with tumor development. Sequencing data were analyzed to call tumor specific single nucleotide variants (SNV), small insertions and deletions (InDels), copy number alterations (CNA) and gene fusions and rearrangements. Results: Overall, 472 ovarian cancer patients underwent somatic and/or germline NGS analysis, the BRCA1 and BRCA2 genes sequenced in this study covers all targeted coding exons and exon-intron boundaries. Among these patients, 54/472 (11.4%) patients carried BRCA( BRCA1/2) mutations. Inside, there were 43/472 (9.1%) patients occurred somatic BRCA mutations, 62.8% (27/43) of variants were in BRCA1 and 37.2% (16/43) were in BRCA2. Furthermore, 3 cases carried BRCA1 and BRCA2 somatic co-mutation, of which only 1 showed BRCA1/ BRCA2 copy number losses. In 54 OC patients who carried BRCA mutations, 10 patients occured copy number alterations, of which 6 patients showed BRCA1 copy number losses, 4 patients showed BRCA2 copy number losses, and 1 patient showed BRCA2 copy number gains. Germline BRCA variant was detected in 18/472 (3.8%) patients, 66.7% (12/18) of variants were in BRCA1 and 33.3% (6/18) were in BRCA2. Of the 12 BRCA1 germline mutations, 11 were pathogenic heterozygous mutations (c.2679_2682del; c.2101_2102del; c.5085_5086insT; c.1660G > T; c.4810C > T; c.1504_1508del; c.1465G > T; c.1480C > T; c.2110_2111del; c.4185+1G > A; c.81-2A > G), one was likely pathogenic heterozygous mutation (c.5216A > G). Of the 6 BRCA 2 germline mutations, four were pathogenic heterozygous mutations (c.5722_5723del; c.5291C > G; c.5164_5165del; c.3109C > T), one was likely pathogenic heterozygous mutation (c.869_870del), and one was uncertain significance heterozygous mutation (c.7976+3A > G). Conclusions: This study revealed the molecular features of BRCA1 and BRCA2 in Chinese ovarian cancer patients, which could help to identify therapeutic targets and personalize therapy management, leading to improved patient outcomes as predictive biomarkers or platinum-based therapy.

Expression of BRCA2 in Ovarian Tumor Tissues and Its Clinical Significance

Expression of Sox2 in Human Ovarian Epithelial Carcinoma.

BRCA mutations in the manifestation and treatment of ovarian cancer.

Expression of BRCA1 Protein in Primary Epithelial Ovarian Cancer

Expression of BRCA1 and Its Relationship with C-erbB-2 and Ki67 in Sporadic Breast Cancer

Germline and Tumor BRCA1/2 Mutations in Chinese High Grade Serous Ovarian Cancer Patients.

Clinical Significance and Prognostic Value of Extracellular Signal-Regulated Kinases in Epithelial Ovarian Cancer

[Expression and Clinical Significance of DNAJB11 in Epithelial Ovarian Cancer].

The landscape of BRCA1 and BRCA2 alterations in Chinese ovarian cancer patients.

Expression of HER-2 and TOPO- Ⅱα in Ovarian Epithelial Cancer and Its Clinical Significance

Association of somatic mutations in BRCA2 BRC domain with chemotherapy sensitivity and survival in high grade serous ovarian cancer

BRCA1/2 Serves as a Biomarker for Poor Prognosis in Breast Carcinoma

Detection of clinically important BRCA gene mutations in ovarian cancer patients using next generation sequencing analysis

Low Levels of BRCA1 Protein Expression Predict a Worse Prognosis in Stage I–II Colon Cancer

BRCA2 gene mutation in cancer.

Expression of DNA Damage Response Proteins and Associations with Clinicopathologic Characteristics in Chinese Familial Breast Cancer Patients with BRCA1/2 Mutations.

[Clinical Significance of Targeting Drug-Based Molecular Biomarkers Expression in Ovarian Clear Cell Carcinoma].

Identification of Molecular Markers Associated With Ovarian Cancer Prognosis Using Bioinformatics Analysis

Brca1 And Brca2 Mutations In Ovarian Cancer Patients From China: Association Of Ethnic-Specific Mutations In Brca1 With An Increased Risk Of Ovarian Cancer

P1.03-27 Somatic Mutations in BRCA2 Genes Are Associated with Prognosis in Chinese Non-Small-Cell Lung Cancer Patients

Clinical Significance of FOXP3 Expression in BRCA1/2-Mutant Breast Cancer